Table 1 Baseline characteristics of patients with plasma cell disorders.
Description | MGUS | SMM | MM | PCL |
|---|---|---|---|---|
N patients | 4 | 3 | 12 | 2 |
Gender = female | 1 (25.0) | 0 (0.0) | 1 (8.3) | 1 (50.0) |
Age, years | 69.0 [62.0, 81.0] | 57.0 [57.0, 64.0] | 67.0 [57.0, 76.0] | 63.5 [58.0, 69.0] |
Prior lines of therapy | 0.0 [0.0, 0.0] | 0.0 [0.0, 0.0] | 4.5 [0.0, 8.0] | 6.5 [6.0, 7.0] |
HDM + ASCT | 0 (0.0) | 0 (0.0) | 10 (83.3) | 2 (100.0) |
BM plasmocytosis, % | 8.4 [7.1, 9.1] | 18.7 [11.5, 21.3] | 58.7 [27.5, 91.0] | 73.2 [50.0, 96.4] |
Ki67+ PC, % | 22.1 [16.0, 40.5] | 27.3 [24.1, 39.4] | 37.3 [6.4, 93.3] | 78.9a |
Salmon–Durie stage, I-II-III | 0 (0.0) - 1 (8.3) - 10 (82.3) | |||
Type of HC | ||||
A | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
G | 2 (50.0) | 2 (66.7) | 8 (66.7) | 1 (50.0) |
None | 2 (50.0) | 1 (33.3) | 3 (25.0) | 1 (50.0) |
Type of LC = lambda | 2 (50.0) | 1 (33.3) | 3 (25.0) | 1 (50.0) |
Monoclonal component, g/l | 3.1 [3.1, 3.1] | 6.0 [2.1, 10.0] | 16.5 [3.8, 39.9] | 4.2 [4.2, 4.2] |
